Wedbush Raises CNC PT To $37

Wedbush has raised the Price Target on Centene

from $31 to $37 a share. Wedbush writes, “Our Increased Estimates Reflect our Belief that Utilization and Flu Trends Remain Moderate. We also have confidence in the company's claims clarity and rapid response to outliers and see further upside potential from robust medical management and updated enrollment numbers from March in several markets.” CNC is rated Outperform and traded at $32.11 yesterday at closing.